DAB486IL-2 data

SRGN published data from separate Phase I trials of DAB486IL-2 in chemotherapy-resistant cancer patients. Data from both trials had been reported previously. The article in the Journal of Clinical Oncology described five patients with cutaneous T cell lymphoma (CTCL). One patient attained a complete resolution of cutaneous disease, which has been sustained without any further treatment for more than 33 months. Two other patients achieved partial responses of 17-plus and 4 months' duration.

A second Phase I study of 23 patients whose tumors had previously expressed the p55 component of the IL-2 receptor was reported in Cancer Research. Two patients had partial responses and four patients had tumor reduction not qualifying for an objective response. The study concluded that the presence of p55 expression on tumor cells is necessary but possibly not sufficient to achieve a tumor response. ...